多激素PIT-1阳性垂体腺瘤:系统综述与单中心系列研究
本研究通过系统综述汇总1990至2020年PP1与SS3腺瘤的临床系列,并对比2012至2019年单中心手术腺瘤数据。综述中99%为巨大腺瘤、18%为巨腺瘤(>4cm),31.8%接受放疗、22.9%多次手术;单中心20例PP1与1146例非PP1在切除程度、大小、再手术、放疗率、p53及MIB-1上无统计学显著差异。结论不支持PP1腺瘤更具侵袭性。
要点
- 综述中PP1/SS3腺瘤99%为巨大腺瘤,18%为>4cm巨腺瘤,31.8%接受放疗。
- 单中心20例PP1与1146例非PP1在切除程度、再手术、放疗率等无显著差异。
- 现有数据不支持PP1腺瘤比非PP1腺瘤更具侵袭性。
核心结论
- 单中心大样本比较未提示PP1腺瘤比非PP1腺瘤更具侵袭性。
- 需进一步研究以识别临床持续更具侵袭性的垂体腺瘤病理亚型。
研究设计与样本
- 系统综述检索Medline和Google Scholar 1990至2020年PP1与SS3腺瘤临床系列,遵循PRISMA指南。
- 纳入报告PP1或SS3病理且报告术后临床结局的研究。
- 单中心回顾2012至2019年手术治疗的垂体腺瘤,比较PP1与非PP1。
主要发现
- 综述中PP1或SS3腺瘤99%为巨大腺瘤,18%为巨腺瘤(>4cm)。
- 综述中31.8%患者接受放疗,22.9%因垂体瘤接受多次手术。
- 单中心20例PP1腺瘤与1146例非PP1腺瘤在切除程度、大小、既往手术次数、未来再手术、放疗率、p53染色或MIB-1标记指数上无统计学显著差异。
关键数值与推荐
- PP1腺瘤定义为符合2017年WHO分类中多激素PIT-1阳性腺瘤标准。
- 巨腺瘤定义为>4cm。
临床怎么用
- PP1腺瘤可按非PP1腺瘤的常规手术和辅助治疗策略管理,无需因该亚型预设更强侵袭性。
- 术后放疗和多次手术在PP1/SS3综述人群中较常见,应个体化评估。
局限性
- 单中心PP1样本量较小(20例),可能限制统计效能。
- 综述数据来自异质性临床系列,可能存在报告偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The 2017 World Health Organization classification of pituitary adenomas identified the plurihormonal PIT-1-positive (PP1) adenoma as a distinct subtype. The reported data suggest that PP1 adenomas encompass the former class of silent subtype 3 (SS3) adenomas and might have an aggressive phenotype. In the present study, we summarized the current clinical data on PP1 and SS3 adenomas and compared the reported data with the data from a single institutional cohort. METHODS: Medline and Google Scholar were searched from 1990 to 2020 for clinical series of PP1 and SS3 adenomas in accordance with the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines. Studies were included if they had reported pituitary pathology as PP1 or SS3 adenomas and had reported the clinical outcomes after surgical intervention. To better define the PP1 phenotype compared with non-PP1 adenomas, we also reviewed the adenomas treated surgically at our institution from 2012 to 2019. RESULTS: Of all the tumors reported in the studies as PP1 or SS3, 99% were macroadenomas and 18% were giant adenomas (>4 cm). Of the reported patients, 31.8% had received radiotherapy, and 22.9% had undergone multiple surgeries for their pituitary tumor. In our single-center experience, 20 patients had an adenoma that met the criteria for a PP1 adenoma. Compared with the 1146 non-PP1 tumors, the PP1 tumors did not show statistically significant differences in the extent of resection, size, number of previous surgeries, future reoperations, rate of radiotherapy, p53 staining, or MIB-1 labeling index. CONCLUSIONS: The findings from the present large, single-center study comparing PP1 and non-PP1 adenomas do not suggest that PP1 tumors are more aggressive. Further work is warranted to identify the pathologic subtypes of pituitary adenomas that are consistently more clinically aggressive.
引用
- Andrews JP, Joshi RS, Pereira MP, et al. Plurihormonal PIT-1-Positive Pituitary Adenomas: A Systematic Review and Single-Center Series. World Neurosurg. 2021. PMID: 33862299. doi:10.1016/j.wneu.2021.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。